Name: RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG)
Brand: CP153
SKU: CP153
Availability: InStock

Skip to the beginning of the images gallery

Technical Data Sheet Safety Data Sheet CoA

Product Details

The RMP1-14-CP153 monoclonal antibody is a chimeric version of the original RMP1-14 antibody. The variable domain sequences are identical to the original RMP1-14 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. The RMP1-14-CP153 antibody also contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. RMP1-14-CP153 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.

Specifications

Isotype	Mouse IgG2a, κ
Recommended Isotype Control(s)	RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer	InVivoPure pH 7.0 Dilution Buffer
Conjugation	This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Mutations	LALA-PG
Immunogen	Syrian Hamster BKH cells transfected with mouse PD-1 cDNA
Reported Applications	in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody
Formulation	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin	<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay
Aggregation	<5% Determined by DLS
Purity	>95% Determined by SDS-PAGE
Sterility	0.2 µm filtration
Production	Purified from CHO cell supernatant in an animal free facility
Purification	Protein G
Molecular Weight	150 kDa
Murine Pathogen Tests	Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative
Storage	The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.